Latest On Curis, Inc (CRIS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-04 23:54 EST | News | Curis GAAP EPS of -$0.12 misses by $0.01, revenue of $2.3M misses by $0.29M | N/A |  |
| 2023-05-04 23:54 EST | News | Curis, Inc. (CRIS) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-03 22:39 EST | News | Curis Q1 2023 Earnings Preview | N/A | |
| 2023-04-06 12:25 EST | News | Curis to grant stock options for 135.45K shares to new hire | N/A | |
| 2023-03-14 03:20 EST | News | Curis, Inc. (CRIS) Q4 2022 Earnings Call Transcript | N/A | |
About Curis, Inc (CRIS):
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors. The company's products in pipeline include CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; read more...and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments to identify therapeutic opportunities. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.
General
- Name Curis, Inc
- Symbol CRIS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 28
- Last Split Factor1:5
- Last Split Date2018-05-30
- Fiscal Year EndDecember
- IPO Date2000-08-01
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.curis.com
Valuation
- Price/Sales (Trailing 12 Mt.) 39.82
- Enterprise Value Revenue 84.55
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.39
- Next Year EPS Estimate -$0.43
- Next Quarter EPS Estimate -$0.07
- Profit Margin -276%
- Operating Margin -230%
- Return on Assets -13%
- Return on Equity -62%
- Revenue 10.84 million
- Earnings Per Share -$0.91
- Revenue Per Share $0.22
- Gross Profit 10.3 million
- Quarterly Earnings Growth -8%
Highlights
- Market Capitalization 1.02 billion
- EBITDA -23119000
- PE Ratio -0.69
- Analyst Target Price $16.75
- Book Value Per Share $1.97
Share Statistics
- Shares Outstanding 91.51 million
- Shares Float 44.73 million
- % Held by Insiders 690%
- % Held by Institutions 26.31%
- Shares Short 4.76 million
- Shares Short Prior Month 2.1 million
- Short Ratio 2.52
- Short % of Float 6%
- Short % of Shares Outstanding 5%
Technicals
- Beta 3.04
- 52 Week High $13.44
- 52 Week Low $0.62
- 50 Day Moving Average 10.17
- 200 Day Moving Average 5.39
Dividends
- Dividend Date 2018-05-30
- ExDividend Date N/A
- Dividend Yield 0%
Curis, Inc (CRIS) Dividend Calendar:
CRIS's last dividend payment was made to shareholders on May 30, 2018.
Curis, Inc (CRIS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Curis, Inc (CRIS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Curis, Inc (CRIS) Chart:
Curis, Inc (CRIS) News:
Below you will find a list of latest news for Curis, Inc (CRIS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Curis, Inc (CRIS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest CRIS Trades:
Curis, Inc (CRIS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-08-04 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-04 | 8-K (Current report) | |
| 2020-06-22 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-22 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-12 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-06-11 | 8-K (Current report) | |
| 2020-06-11 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-10 | 8-K (Current report) | |
| 2020-05-12 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-05-12 | 8-K (Current report) | |
| 2020-04-27 | 8-K (Current report) | |
| 2020-04-22 | DEF 14A (Other definitive proxy statements) | |
| 2020-04-22 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-04-17 | 8-K (Current report) | |
| 2020-04-10 | PRE 14A (Other preliminary proxy statements) | |
| 2020-03-19 | 10-K (Annual report [Section 13 and 15(d), not S-K Item 405]) | |
| 2020-03-19 | 8-K (Current report) | |
| 2020-03-06 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-03-06 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-03-06 | 8-K (Current report) | |
Curis, Inc (CRIS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Curis, Inc (CRIS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 690%
Institutional Ownership: 2631%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-01-24 | James E Dentzer | President & CEO | Sell | 3,094.00 | 1.64 | 5,076.33 | 42,158.00 | |
| 2020-01-23 | James E Dentzer | President & CEO | Sell | 3,658.00 | 1.69 | 6,181.65 | 45,252.00 | |
| 2019-01-24 | James E Dentzer | President & CEO | Sell | 3,094.00 | 1.16 | 3,576.97 | 41,639.00 | |
| 2019-01-23 | Lori Anne Kunkel | Director | Sell | 14,800.00 | 1.05 | 15,581.44 | 22,200.00 | |
| 2019-01-23 | Robert Martell | Head of Research & Development | Sell | 5,500.00 | 1.07 | 5,900.40 | 23,027.00 | |
| 2019-01-23 | MARTYN D GREENACRE | Director | Sell | 18,500.00 | 1.05 | 19,474.95 | 26,089.00 | |
| 2019-01-23 | KENNETH I KAITIN | Director | Sell | 14,800.00 | 1.05 | 15,587.36 | 28,121.00 | |
| 2019-01-23 | Marc Rubin | Director | Sell | 18,500.00 | 1.05 | 19,476.80 | 28,819.00 | |
| 2019-01-23 | James E Dentzer | President & CEO | Sell | 2,397.00 | 1.09 | 2,612.73 | 44,733.00 | |
| 2018-01-22 | David Tuck | Chief Medical Officer | Buy | 133,750.00 | 169,424.00 | | ||
| 2018-01-22 | Lori Anne Kunkel | Director | Buy | 185,000.00 | 185,000.00 | | ||
| 2018-01-22 | Robert Martell | Director | Buy | 185,000.00 | 185,000.00 | | ||
| 2018-01-22 | James E Dentzer | Chief Financial Officer | Buy | 206,250.00 | 212,011.00 | | ||
| 2018-01-22 | KENNETH I KAITIN | Director | Buy | 185,000.00 | 214,607.00 | | ||
| 2018-01-22 | MARTYN D GREENACRE | Director | Buy | 185,000.00 | 222,945.00 | | ||
| 2018-01-22 | Marc Rubin | Director | Buy | 185,000.00 | 236,596.00 | | ||
| 2018-01-22 | Ali Ph.D. Fattaey | President & CEO | Buy | 206,250.00 | 322,140.00 | | ||
| 2017-11-16 | Marc Rubin | Director | Buy | 25,000.00 | 0.98 | 24,500.00 | 51,596.00 | |
| 2017-11-15 | Ali Ph.D. Fattaey | President & CEO | Buy | 50,000.00 | 1.06 | 53,000.00 | 115,890.00 | |